Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has puzzled medical researchers for 40 years. Now, a new study by researchers at Case ...

An experimental treatment method has shown promise in fighting a hard-to-treat form of bladder cancer known as BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). BCG (Bacillus ...

CLEVELAND, Ohio — A shift toward personalized treatment for breast cancer, ways to help patients live longer without their cancer worsening and a shorter but equally effective treatment for a ...

A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by an innovative form of immune therapy. For families facing a disease that ...

There’s a new twist in the fight against bladder cancer — and it’s delivering game-changing results. In a recent clinical trial, a pretzel-shaped device that slowly releases chemotherapy drugs ...

A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer​.

A new treatment strategy tested by UCLA researchers could offer new hope for men whose prostate cancer has returned after initial treatment. This approach could also help delay the need for hormone ...

From smart pill bottles that help people remember to take their meds to calls for better menopausal symptom relief for women with breast cancer to intriguing hints at what drives dormant tumor cells ...

Nuvalent, Inc. (NASDAQ: NUVL) on Monday reported topline results from its ALKOVE-1 Phase 1/2 trial. The study evaluated neladalkib in tyrosine kinase inhibitor (TKI)-pretreated patients with advanced ...

Cancer treatment is hard enough without bureaucratic and policy hurdles, two doctors argue. Better advocacy is necessary.

Justin Stebbing does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...